CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Project Number||pCODR 10197|
|Strength||15 mg / 6.14 mg and 20 mg / 8.19 mg|
|Funding Request||For the treatment of adult patients with metastatic gastric cancer or adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior lines of chemotherapy including a fluoropyrimidine, a platinum, and either a taxane or irinotecan and if appropriate with HER2/neu-targeted therapy|
|Review Status||Notification to Implement Issued|
|Pre Noc Submission||Yes|
|NOC Date||November 19, 2019|
|Manufacturer||Taiho Pharma Canada, Inc.|
|Sponsor||Taiho Pharma Canada, Inc.|
|Submission Date||September 3, 2019|
|Submission Deemed Complete||September 17, 2019|
|Submission Type||New Indication|
|Stakeholder Input Deadline ‡||September 17, 2019|
|Check-point meeting||November 6, 2019|
|pERC Meeting||February 20, 2020|
|Initial Recommendation Issued||March 5, 2020|
|Feedback Deadline ‡||March 19, 2020|
|pERC Reconsideration Meeting (target date)|
|Final Recommendation Issued||March 24, 2020|
|Notification to Implement Issued||April 8, 2020|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.